NRXP
NRx Pharmaceuticals, Inc.
Industry
Biotechnology
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Loading...
Open
1.18
Mkt cap
15M
Volume
200K
High
1.23
P/E Ratio
-0.57
52-wk high
7.33
Low
1.18
Div yield
N/A
52-wk low
1.10

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.